Giampaolo Bianchini

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 20

Top Topics

Positive Breast Cancer

Epidermal Growth Factor Receptor

Ejection Fraction

Top Venues

Nature medicine

NPJ breast cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Nadia Harbeck, Eva Ciruelos Gil, Guy Jerusalem, Volkmar Müller, Naoki Niikura, Giuseppe Viale, Rupert Bartsch, Christian Kurzeder, Michaela J Higgins, Caitriona Cahir, Sally Baron-Hay, María Gión, Valentina Guarneri, Giampaolo Bianchini, Hans P M W Wildiers, Santiago Escrivá-de-Romaní, Manoj Prahladan, Helen Bridge, Nataliya Kuptsova-Clarkson, Nana Scotto, Sunil Verma, Nancy U Lin, null null
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nature medicine (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S Seitz, Tyler J Nielsen, Marc Thill, Antonio Antón-Torres, Stefania Russo, Eva Ciruelos Gil, Brock L Schweitzer, Douglas Teller Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Gyorffy Balazs, Marco Colleoni, Catherine M Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Blasi, Maurizio Callari, Lajos Pusztai, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Luca Licata, Giulia Viale, Mario Giuliano, Curigliano Giuseppe, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Luca Licata, Marco Barreca, Barbara Galbardi, Matteo Dugo, Giulia Viale, Balàzs Győrffy, Thomas Karn, Lajos Pusztai, Luca Gianni, Maurizio Callari, Giampaolo Bianchini
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy. British journal of cancer (2023)
Xiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, Daniel Egle, Maurizio Callari, Begoña Bermejo, Matteo Dugo, Claudio Zamagni, Marc Thill, Anton Anton, Stefania Zambelli, Stefania Russo, Eva Maria Ciruelos, Richard Greil, Balázs Győrffy, Vladimir Semiglazov, Marco Colleoni, Catherine M Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Biasi, Robert S Seitz, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini, H Raza Ali
Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature (2023)
Mattia Garutti, Gaia Griguolo, Andrea Botticelli, Giulia Buzzatti, Carmine De Angelis, Lorenzo Gerratana, Chiara Molinelli, Vincenzo Adamo, Giampaolo Bianchini, Laura Biganzoli, Curigliano Giuseppe, Michelino De Laurentiis, Alessandra Fabi, Antonio Frassoldati, Alessandra Gennari, Caterina Marchio, Francesco Perrone, Giuseppe Viale, Claudio Zamagni, Alberto Zambelli, Lucia Del Mastro, Sabino De Placido, Valentina Guarneri, Marina Chiara Garassino, Fabio Puglisi
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. Cancers 14 (8) (2022)
Luca Gianni, Marco Colleoni, Giancarlo Bisagni, Mauro Mansutti, Claudio Zamagni, Lucia Del Mastro, Stefania Zambelli, Giampaolo Bianchini, Antonio Frassoldati, Ilaria Maffeis, Pinuccia Valagussa, Giuseppe Viale
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. NPJ breast cancer 8 (1) (2022)
Giampaolo Bianchini, Grazia Arpino, Laura Biganzoli, Sara Lonardi, Fabio Puglisi, Daniele Santini, Matteo Lambertini, Giovanni Luigi Pappagallo
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. Cancers 14 (4) (2022)
Lucia Viganò, Alberta Locatelli, Adele Ulisse, Barbara Galbardi, Matteo Dugo, Diego Tosi, Carlo Tacchetti, Tiziana Daniele, Balázs Győrffy, Lorenzo Sica, Marina Macchini, Milvia Zambetti, Stefania Zambelli, Giampaolo Bianchini, Luca Gianni
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (10) (2022)
Hajnalka Laura Pálinkás, Lőrinc Pongor, Máté Balajti, Ádám Nagy, Kinga Nagy, Angéla Békési, Giampaolo Bianchini, Beáta G Vértessy, Balázs Győrffy
Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer. International journal of molecular sciences 23 (2) (2022)
Elisa Agostinetto, Filippo Montemurro, Fabio Puglisi, Carmen Criscitiello, Giampaolo Bianchini, Lucia Del Mastro, Martino Introna, Carlo Tondini, Armando Santoro, Alberto Zambelli
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers 14 (9) (2022)
Paolo Tarantino, Chiara Corti, Peter Schmid, Javier Cortes, Elizabeth A Mittendorf, Hope Rugo, Sara M Tolaney, Giampaolo Bianchini, Fabrice Andre, Curigliano Giuseppe
Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ breast cancer 8 (1) (2022)
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, Luca Gianni
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nature reviews. Clinical oncology (2021)
Cristina Guardia, Giampaolo Bianchini, Oriol Arpí-LLucià, Silvia Menendez, David Casadevall, Barbara Galbardi, Matteo Dugo, Sonia Servitja, Juan Carlos Montero, Luis Soria-Jiménez, MohammadA Sabbaghi, Raul Peña, Juan Madoz-Gúrpide, Belen Lloveras, Ana Lluch, Pilar Eroles, Joaquin Arribas, Atanasio Pandiella, Luca Gianni, Federico Rojo, Ana Rovira, Joan Albanell
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (18) (2021)
Giulia Viale, Luca Licata, Lorenzo Sica, Stefania Zambelli, Patrizia Zucchinelli, Alessia Rognone, Daniela Aldrighetti, Rosa Di Micco, Veronica Zuber, Marcella Pasetti, Nadia Di Muzio, Mariagrazia Rodighiero, Pietro Panizza, Isabella Sassi, Giovanna Petrella, Stefano Cascinu, Oreste Davide Gentilini, Giampaolo Bianchini
Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. The oncologist 25 (7) (2020)